Shanghai Hengrui Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-12-04
- Employees
- -
- Market Cap
- -
- Website
- http://www.shhrp.com
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Non-Hodgkin's Lymphoma
- Interventions
- Drug: SHR-A1912; R-Chemo
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT06104553
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
Phase 2
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: SHR-1819 injection
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06012812
- Locations
- 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT05836948
- Locations
- 🇨🇳
Zhejiang Tumor Hospital, Hangzhou, Zhejiang, China
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: AdebrelimabBiological: SHR-1802Drug: Carboplatin/CisplatinDrug: Paclitaxel/Nab-Paclitaxel/Pemetrexed
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT05794477
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy
Phase 3
Completed
- Conditions
- Postsurgical Pain Management
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 294
- Registration Number
- NCT05769855
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management
Phase 2
Recruiting
- Conditions
- Thoracoscopic Lobectomy
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05744674
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT05740202
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
Phase 1
Recruiting
- Conditions
- Advanced Or Metastatic Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT05735275
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 395
- Registration Number
- NCT05701709
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.
Phase 1
Active, not recruiting
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: SHR-1707 placebo
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05681819
- Locations
- 🇨🇳
The First Affiliated Hospital Of USTC, Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath